Evidence map›Paper›PMID 35357903›Full record

Trial reportJCO precision oncology2022

Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer.

Thanh H Dellinger, Ernest S Han, Mustafa Raoof, Byrne Lee, Xiwei Wu, Hyejin Cho, Ting-Fang He, Peter Lee, Marianne Razavi, Winnie S Liang and 14 more

Erratum issuedOpen access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Thanh H DellingerDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0003-1855-1989
Ernest S HanDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0001-6224-8544
Mustafa RaoofDivision of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0003-4710-2226
Byrne LeeDepartment of Surgery, Stanford University, Stanford, CA.
Xiwei WuIntegrative Genomics Core, City of Hope National Medical Center Beckman Research Institute, Duarte, CA.
Hyejin ChoIntegrative Genomics Core, City of Hope National Medical Center Beckman Research Institute, Duarte, CA.ORCID 0000-0002-9954-8118
Ting-Fang HeImmuno-oncology Core, City of Hope National Medical Center Beckman Research Institute, Duarte, CA.
Peter LeeImmuno-oncology Core, City of Hope National Medical Center Beckman Research Institute, Duarte, CA.ORCID 0000-0002-2660-4377
Marianne RazaviWomen's Cancer Center, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-1070-3848
Winnie S LiangTranslational Genomics Research Institute, Phoenix, AZ.ORCID 0000-0002-5698-7735
Daniel SchmolzeDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-6947-2546
Saul J PricemanHematology & Hematopoietic Cell Transplantation and Immuno-Oncology, City of Hope National Medical Center Beckman Research Institute, Duarte, CA.
Stephen LeeDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.
Wei-Chien LinDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.
Jeff F LinDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.
Mehdi KebriaDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-6779-2589
Amy HakimDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.
Nora RuelBiostatistics Core, City of Hope National Medical Center Beckman Research Institute, Duarte, CA.
Daphne B StewartDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
Edward W WangDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
Benjamin I PazDepartment of Surgery, Stanford University, Stanford, CA.
Mark T WakabayashiDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0003-2334-6875
Mihaela C CristeaDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
Lorna Rodriguez-RodriguezDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-5909-1774
City Of Hope National Medical Center · USStanford University · USTranslational Genomics Research Institute · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

purposeHyperthermic intraperitoneal chemotherapy (HIPEC) confers a survival benefit in epithelial ovarian cancer (EOC) and in preclinical models. However, the molecular changes induced by HIPEC have not been corroborated in humans. PATIENTS AND

methodsA feasibility trial evaluated clinical and safety outcomes of HIPEC with cisplatin during optimal cytoreductive surgery (CRS) in patients with EOC diagnosed with stage III, IV, or recurrent EOC. Pre- and post-HIPEC biopsies were comprehensively profiled with genomic and transcriptomic sequencing to identify mutational and RNAseq signatures correlating with response; the tumor microenvironment was profiled to identify potential immune biomarkers; and transcriptional signatures of tumors and normal samples before and after HIPEC were compared to investigate HIPEC-induced acute transcriptional changes.

resultsThirty-five patients had HIPEC at the time of optimal CRS; all patients had optimal CRS. The median progression-free survival (PFS) was 24.7 months for primary patients and 22.4 for recurrent patients. There were no grade 4 or 5 adverse events. Anemia was the most common grade 3 adverse event (43%). Hierarchical cluster analyses identified distinct transcriptomic signatures of good versus poor responders to HIPEC correlating with a PFS of 29.9 versus 7.3 months, respectively. Among good responders, significant HIPEC-induced molecular changes included immune pathway upregulation and DNA repair pathway downregulation. Within cancer islands, % programmed cell death protein 1 expression in CD8+ T cells significantly increased after HIPEC. An exceptional responder (PFS 58 months) demonstrated the highest programmed cell death protein 1 increase. Heat shock proteins comprised the top differentially upregulated genes in HIPEC-treated tumors.

conclusionDistinct transcriptomic signatures identify responders to HIPEC, and preclinical model findings are confirmed for the first time in a human cohort.

Indexed as

Carcinoma, Ovarian EpithelialHyperthermic Intraperitoneal ChemotherapyOvarian NeoplasmsFeasibility StudiesFemaleHumansNeoplasm Recurrence, LocalTumor Microenvironment

Identifiers

PMID35357903
PMCPMC8984280
OpenAlexW4221112537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.